AIFF

Firefly Neuroscience, Inc. operates as a medical technology company focused on developing artificial intelligence-powered solutions for brain health assessment and diagnostics. Headquartered in Toronto, Canada, the company specializes in neuroscience applications that analyze brain activity patterns to support clinical decision-making in mental health and neurological conditions. Firefly's primary product is its AI-driven platform that processes electroencephalogram (EEG) data to assist healthcare providers in evaluating conditions such as depression, ADHD, and other neuropsychiatric disorders. The company's technology aims to provide objective biomarker-based assessments that complement traditional diagnostic methods. Firefly targets psychiatrists, neurologists, and mental health professionals seeking data-driven tools to enhance diagnostic accuracy and treatment monitoring. The company operates in the growing digital health and neurotechnology sector, where demand for precision medicine approaches continues to expand. Recent developments include ongoing clinical validation studies and efforts to establish partnerships with healthcare providers and research institutions. As a development-stage company, Firefly focuses on regulatory pathways, clinical evidence generation, and market adoption strategies to position its technology within mental health care workflows. The company trades on the NASDAQ Capital Market under the ticker symbol AIFF following its business combination and public listing, providing it with capital access to advance its commercialization objectives.